In terms of our current roll-out, we know that we will have around 1.5 million doses of Pfizer vaccine left over this year that will allow us to start the booster programme, and conversations are happening with Pfizer and with other vaccine manufacturers around the supply of vaccines for boosters. We have, as I indicated just before, options for Novavax early in the new year, and there is some international evidence that suggests that that could actually be a good booster vaccine for New Zealand's purposes as well. So, in terms of those discussions, we do take a different approach to some other countries who we like to compare ourselves with when those discussions are happening; we announce them once we've got a signed deal. Other countries have been announcing them once they've got, if you like, a handshake or an indication of what's going to be possible. We don't do it until the deal is signed and we have absolute certainty, and that's the approach that we're going to continue to do.